



Date: 08th April, 2024.

To
The Corporate Relations Department
BSE Limited,
Dalal Street, P.J Towers,
Mumbai- 400001.

Dear Sir /Madam,

Sub: Outcome of the Board Meeting.

Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Scrip Code: 524636

Pursuant to Regulation 30 read with Part A of Schedule III of the Listing Regulations, we hereby inform you that the Board of Directors of the Company at its Board Meeting held today, **April 08, 2024**, inter-alia, considered and approved the following:

1. Increase in Authorized Share Capital of the Company:

To increase the Authorized Share Capital of the Company from existing Rs. 35,00,00,000 (Rupees Thirty-Five Crore) divided into 3,50,00,000 (Three Crore Fifty Lakhs) Equity Shares of Rs.10/- each **TO** Rs. 37,50,00,000 (Rupees Thirty-Seven Crore Fifty lakhs only) divided into 3,75,00,000 (Three Crore Seventy-Five Lakhs) Equity Shares of Rs. 10/- each ranking pari passu in all respects with the existing Equity Shares of the Company as per the Memorandum and Articles of Association of the Company, subject to the approval of shareholders, in accordance with the applicable provisions of the Companies Act, 2013 and rules made there under.

2. Issue upto 20,00,000 equity shares of the Company on preferential basis for consideration for Cash:

Issue upto 20,00,000 (Twenty Lakhs Only) equity shares on preferential basis ("**Preferential Issue**") to the persons who come under Proposed Promoter/Promoters group, subject to the approval of shareholders, in accordance with the Companies Act, 2013 read with the rules made there under and Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("**SEBI ICDR Regulations**") read with other applicable regulations, if any, at a price not being lower than the price determined in accordance with Chapter V of SEBI ICDR Regulations and other applicable regulations.

Sai Sudhakar



OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)
(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.
Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.
E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038



Oxygenta

Attached **Annexure – A** about the details to be disclosed pursuant to Regulation 30 of Listing Regulations read with SEBI Circular bearing reference no. SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123.

3. *Constituted a committee for allotment of securities known as "Allotment Committee."*
4. **Finalisation of date, day, Time, Venue, Cut-off date and Notice for the Extra-Ordinary General Meeting of the Company:**

An Extra Ordinary General Meeting (EGM) is scheduled to be held on Thursday, May 09, 2024 at 03.00 P.M. at the Registered office of the Company situated at Survey no. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy District, Telangana State – 502291.

The cut-off date for the purpose of remote e-voting and voting at the EGM dated May 09, 2024 is May 02, 2024.

5. **Appointment of scrutinizer**

Considered and approved the appointment of **Mr. N.V.S.S. Suryanarayana Rao**, Practicing Company Secretary, (M.No. A5868), Hyderabad, as the Scrutinizer to scrutinize the e-voting process and polling in a fair and transparent manner for the purpose of Extra-ordinary General Meeting of the Company be held on Thursday, May 09, 2024 at 03.00 P.M. and he has communicated his willingness to be appointed and will be available for same purpose.


The aforesaid Board Meeting commenced at 4.00 P.M. and concluded at 5.45 P.M.

Kindly take the above information on record.

Thanking you,

Yours Faithfully

For **OXYGENTA PHARMACEUTICAL LIMITED**



VANKINENI SAI SUDHAKAR

Managing Director

DIN: 00733001



OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038

Annexure-A

Preferential Issue of Equity Shares

S.No	Particulars	Remarks -
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Issue of up to 20,00,000 equity shares of Rs.10/- each on Preferential basis to the Proposed Promoter/ Promoter group.
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Issue of equity shares in accordance with the SEBI (ICDR) Regulations, 2018 read with the Companies Act, 2013 and rules made there under.
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Issue upto 20,00,000 equity shares of Rs.10/- each on Preferential basis to the Proposed Promoter/ Promoter group at a price not being lower than the price determined in accordance with the Chapter V of SEBI ICDR Regulations, 2018 and other applicable regulations if any. The issue price approved is Rs 16/- per share.
4.	Additional details to the stock exchange(s): (a). Names of investors	Proposed Promoter/ Promoter group (Group -A) 1. Upto 17,00,000 equity shares of Rs.10/- each on Preferential Basis to Mr. M V S Prasad Reddy. 2. Upto 2,00,000 equity shares of Rs.10/- each on Preferential Basis to M/s. Amigos Molecular Solutions Private Limited. 3. Upto 1,00,000 equity shares of Rs.10/- each on Preferential Basis to Ms. Rachamalla Aparna.
	(b). Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors;	Issue price shall be the price not being lower than the price determined in accordance with the Chapter V of SEBI ICDR Regulations, 2018 and other applicable regulations if any. The issue price approved is Rs 16/- per share.
	(c). In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Not Applicable
	(d). Any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not Applicable

CV Sai Sudhakar

